Background Malaria and helminths diseases are co-endemic in most parts of sub-Saharan
Africa. Immune responses from each of these pathogens interact, and these interactions may …

Background Helminths can modulate the host immune response to Plasmodium falciparum
and can therefore affect the risk of clinical malaria. We assessed here the effect of helminth …

Abstract Background In Ethiopia, the general population is vulnerable to unpredictable
epidemics of Plasmodium falciparum malaria. However, there is little information on the anti …

Malaria is still one of the major public health threats in sub-Saharan Africa. An effective
vaccine could be a sustainable control measure that can be integrated into existing health …

Background GMZ2 is a recombinant malaria vaccine inducing immune responses against
Plasmodium falciparum (Pf) merozoite surface protein-3 and glutamate-rich protein. We …

Background Plasmodium falciparum genetic diversity and multiplicity of infection (MOI) are
parasite features that have been suggested to influence the acquisition of protective …

Background GMZ2 is a fusion protein of Plasmodium falciparum merozoite surface protein 3
(MSP3) and glutamate rich protein (GLURP) that mediates an immune response against the …

Background. GMZ2 is a hybrid protein consisting of the N-terminal region of the glutamate-
rich protein fused in frame to the C-terminal region of merozoite surface protein 3 (MSP3) …

Malaria is a major public health problem in Sub-Saharan Africa. In highly endemic regions
infants, children and pregnant women are mostly affected. An effective malaria vaccine …

Introduction: GMZ2 is a recombinant protein consisting of conserved domains of GLURP and
MSP3, two asexual blood-stage antigens of Plasmodium falciparum, and is designed with …